facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2021
vol. 108
 
Share:
Share:
abstract:
Review paper

The place of hydroxychloroquine in modern dermatology

Aleksandra Dańczak-Pazdrowska
1
,
Adriana Polańska
2

  1. Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznan, Poland
Dermatol Rev/Przegl Dermatol 2021, 108, 178–190
Online publish date: 2021/08/26
View full text Get citation
 
PlumX metrics:
Hydroxychloroquine has been known since the 1940s. It was initially used to treat malaria. Currently, it has a well-established position in the treatment of lupus erythematosus. The knowledge about its benefits is increasing over time. The mechanism of action of hydroxychloroquine reaches far beyond the immunomodulatory effect, and includes a beneficial effect on glycemic control in patients with diabetes and it is believed to have an effect on normalization of lipid levels, including total cholesterol, LDL cholesterol and triglycerides. In treatment of lupus erythematosus hydroxychloroquine allows decreasing the dose of immunosuppressive drugs, thus not only increasing the treatment efficacy, but also reducing the risk of adverse effects. Possible indications for hydroxychloroquine include also granulomatous skin diseases, such as disseminated annular granuloma, cutaneous sarcoidosis, or reactive granulomatous dermatitis. This article discusses the current indications for hydroxychloroquine with focus on recommended therapeutic regimens and monitoring treatment.
keywords:

hydroxychloroquine, lupus erythematosus, autoimmune connective tissue diseases, granulomatous skin diseases



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.